The pathophysiology of abdominal surgical diseases and the therapeutic potential of mesenchymal stem cells

Melih Can Gul

doi:10.5281/zenodo.15832071

Authors

Melih Can Gul Afyonkarahisar State Hospital Department of Gastroenterology Surgery Afyonkarahisar, Türkiye https://orcid.org/0000-0002-6165-1144

DOI:

https://doi.org/10.5281/zenodo.15832071

Keywords:

Mesenchymal stem cells, General surgery, Inflammatory bowel disease, Cirrhosis, Pancreatitis

Abstract

Mesenchymal stem cells (MSCs) represent a promising therapeutic option for abdominal surgical diseases that are refractory to conventional treatments. Their unique immunomodulatory, antifibrotic, and pro-regenerative properties offer a novel biological platform for tissue repair and inflammatory regulation. In this letter, we summarize current evidence regarding MSC applications in key gastrointestinal and hepatopancreatobiliary conditions, including refractory peptic ulcer, inflammatory bowel disease, acute pancreatitis, and decompensated cirrhosis. Specific emphasis is placed on the relevance of administration routes—such as local, intravenous, or portal applications—tailored to each pathology. Notably, MSCs have demonstrated clinical efficacy in promoting mucosal healing, fistula closure, cytokine suppression, and hepatic function improvement. These findings highlight the translational potential of MSC-based interventions in surgical gastroenterology. Further research should aim to standardize delivery protocols and identify optimal patient populations. We believe this concise synthesis may guide future clinical strategies and regenerative innovations in the field.

References

Azizoglu M, Zorba-Yildiz AP, Yilmaz H, Yurtbay G, Catli G, Yavuz G, et al. Regenerative medicine in surgery: stem cells and exosome applications. Cir Cir. 2025;93(1):86-104.

Ko JZ, Johnson S, Dave M. Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. Biomolecules. 2021;11(1):82.

Saleh M, Sohrabpour AA, Mehrabi MR, Seyhoun I, Vaezi AA. Therapeutic approach of adipose-derived mesenchymal stem cells in refractory peptic ulcer. Stem Cell Res Ther. 2021;12(1):515.

Waseem M, Altaf H, Hussain N, Mushtaq S, Siddique S. The role of mesenchymal stem cells in the treatment of ARDS and cytokine storms in COVID‑19. J Clin Trials Exp Investig. 2025;4(1):36‑8.

Xia X, Chan KF, Wong GTY, Wang P, Liu L, Yeung BPM, et al. Mesenchymal stem cells promote healing of nonsteroidal anti-inflammatory drug-related peptic ulcer through paracrine actions in pigs. Sci Transl Med. 2019;11(516):eaat7455.

Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281-90.

Barnhoorn MC, Wasser MNJM, Roelofs H, Maljaars PWJ, Molendijk I, Bonsing BA, et al. Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. J Crohns Colitis. 2020;14(1):64-70.

Ahmed SM, Morsi M, Ghoneim NI, Abdel-Daim MM, El-Badri N. Mesenchymal Stromal Cell Therapy for Pancreatitis: A Systematic Review. Oxid Med Cell Longev. 2018;2018:3250864.

Wang Z, Li T, Zhang Z, Yuan M, Shi M, Wang FS, Linghu EQ, et al. Human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis (MSC-DLC-1): a dose-escalation, phase I trial protocol. BMJ Open. 2023;13(12):e078362.

Lu W, Qu J, Yan L, Tang X, Wang X, Ye A, et al. Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis. Stem Cell Res Ther. 2023;14(1):301.

Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725-31.

Wang X, Wang Y, Lu W, Qu J, Zhang Y, Ye J. Effectiveness and mechanisms of mesenchymal stem cell therapy in preclinical animal models of hepatic fibrosis: a systematic review and meta-analysis. Front Bioeng Biotechnol. 2024;12:1424253.

Ding Y, Li Y, Sun Z, Han X, Chen Y, Ge Y, et al. Cell-derived extracellular vesicles and membranes for tissue repair. J Nanobiotechnology. 2021;19(1):368.

Liu W, Cheng G, Cui H, Tian Z, Li B, Han Y, et al. Theoretical basis, state and challenges of living cell-based drug delivery systems. Theranostics. 2024;14(13):5152-83.

Cheng F, Zhong H, Huang Z, Li Z. Up-to-date meta-analysis of long-term evaluations of mesenchymal stem cell therapy for complex perianal fistula. World J Stem Cells. 2023;15(8):866-75.